Association Between Gene C-1019G Polymorphism and Antidepressant Response in Patients with Major Depressive Disorder: A Meta-analysis

Overview

Journal World J Psychiatry

Publisher Baishideng Publishing Group

Specialty Psychiatry

Date 2024 Oct 30

PMID 39474388

Authors

Huai-Neng Wu

Shuang-Yue Zhu

Li-Na Zhang

Bian-Hong Shen

Lian-Lian Xu

Affiliations

Soon will be listed here.

Abstract

Background: Major depressive disorder (MDD) is a substantial global health concern, and its treatment is complicated by the variability in individual response to antidepressants.

Aim: To consolidate research and clarify the impact of genetic variation on MDD treatment outcomes.

Methods: Adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic search across PubMed, EMBASE, Web of Science, and the Cochrane Library was conducted without date restrictions, utilizing key terms related to MDD, serotonin 1A receptor polymorphism (5-HTR1A), C-1019G polymorphism, and antidepressant response. Studies meeting inclusion criteria were thoroughly screened, and quality assessed using the Newcastle-Ottawa Scale. Statistical analyses, including and values, were used to evaluate heterogeneity and fixed-effect or random-effect models were applied accordingly.

Results: The initial search yielded 1216 articles, with 11 studies meeting criteria for inclusion. Analysis of various genetic models showed no significant association between the 5-HTR1A C-1019G polymorphism and antidepressant efficacy. The heterogeneity was low to moderate, and no publication bias was detected through funnel plot symmetry and Egger's and Begg's tests.

Conclusion: This meta-analysis does not support a significant association between the 5-HTR1A C-1019G polymorphism and the efficacy of antidepressant treatment in MDD. The findings call for further research with larger cohorts to substantiate these results and enhance the understanding of antidepressant pharmacogenetics.

References

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Jackson W, Papakostas G, Rafeyan R, Trivedi M . Recognizing Inadequate Response in Patients With Major Depressive Disorder. J Clin Psychiatry. 2020; 81(3). DOI: 10.4088/JCP.OT19037BR2. View

Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S . Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2008; 150B(1):115-23. DOI: 10.1002/ajmg.b.30783. View

Serretti A, Fabbri C, Pellegrini S, Porcelli S, Politi P, Bellino S . No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. Psychiatry Investig. 2013; 10(2):180-9. PMC: 3687053. DOI: 10.4306/pi.2013.10.2.180. View

Zhao X, Jin Q, Wu L, Huang Y, Li J, Zhu G . Sertraline (Zoloft) response in major depressive disorder is not associated with three 5-HT1A receptor gene polymorphisms (rs6295, rs10042486, or rs1364043) in Chinese-Han patients. Psychiatr Genet. 2011; 22(5):261-2. DOI: 10.1097/YPG.0b013e32834dc44c. View

Noro M, Antonijevic I, Forray C, Kasper S, Kocabas N, Lecrubier Y . 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol. 2010; 25(4):228-31. DOI: 10.1097/YIC.0b013e328338bcf4. View

Schramm E, Klein D, Elsaesser M, Furukawa T, Domschke K . Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. Lancet Psychiatry. 2020; 7(9):801-812. DOI: 10.1016/S2215-0366(20)30099-7. View

Dong Z, Li X, He L, He G, Yu T, Sun X . 5-HTR1A and 5-HTR2A genetic polymorphisms and SSRI antidepressant response in depressive Chinese patients. Neuropsychiatr Dis Treat. 2016; 12:1623-9. PMC: 4938133. DOI: 10.2147/NDT.S93562. View

Hong C, Chen T, Yu Y, Tsai S . Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2005; 6(1):27-33. DOI: 10.1038/sj.tpj.6500340. View

10.

Basu A, Chadda R, Sood M, Kaur H, Kukreti R . Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study. Indian J Med Res. 2015; 142(1):40-5. PMC: 4557249. DOI: 10.4103/0971-5916.162094. View

11.

Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R . The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol. 2004; 7(4):453-60. DOI: 10.1017/S1461145704004687. View

12.

Lin E, Chen P, Chang H, Gean P, Tsai H, Yang Y . Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33(7):1167-72. DOI: 10.1016/j.pnpbp.2009.06.015. View

13.

Zhang K, Xu Q, Xu Y, Yang H, Luo J, Sun Y . The combined effects of the 5-HTTLPR and 5-HTR1A genes modulates the relationship between negative life events and major depressive disorder in a Chinese population. J Affect Disord. 2008; 114(1-3):224-31. DOI: 10.1016/j.jad.2008.07.012. View

14.

Trivedi M . Major Depressive Disorder in Primary Care: Strategies for Identification. J Clin Psychiatry. 2020; 81(2). DOI: 10.4088/JCP.UT17042BR1C. View

15.

Rybak Y, Lai K, Ramasubbu R, Vila-Rodriguez F, Blumberger D, Chan P . Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment. Depress Anxiety. 2021; 38(4):456-467. PMC: 8049072. DOI: 10.1002/da.23135. View

16.

Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N . 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport. 2009; 20(12):1125-8. DOI: 10.1097/WNR.0b013e32832eb708. View

17.

McIntyre R, Lee Y, Carmona N, Subramaniapillai M, Cha D, Lee J . Characterizing, Assessing, and Treating Cognitive Dysfunction in Major Depressive Disorder. Harv Rev Psychiatry. 2018; 26(5):241-249. DOI: 10.1097/HRP.0000000000000171. View

18.

Basu A, Chadda R, Sood M, Kaur H, Kukreti R . A preliminary association study between serotonin transporter (5-HTTLPR), receptor polymorphisms (5-HTR1A, 5-HTR2A) and depression symptom-clusters in a north Indian population suffering from Major Depressive Disorder (MDD). Asian J Psychiatr. 2019; 43:184-188. DOI: 10.1016/j.ajp.2019.05.028. View

19.

Scutt G, Overall A, Scott R, Patel B, Hachoumi L, Yeoman M . Does the 5-HT rs6295 polymorphism influence the safety and efficacy of citalopram therapy in the oldest old?. Ther Adv Drug Saf. 2018; 9(7):355-366. PMC: 6048630. DOI: 10.1177/2042098618770620. View

20.

Huang Y, Battistuzzi C, Oquendo M, Harkavy-Friedman J, Greenhill L, Zalsman G . Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol. 2004; 7(4):441-51. DOI: 10.1017/S1461145704004663. View